AR086252A1 - Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo - Google Patents
Formulacion topica que comprende dipropionato de beclometasona como ingrediente activoInfo
- Publication number
- AR086252A1 AR086252A1 ARP120101554A ARP120101554A AR086252A1 AR 086252 A1 AR086252 A1 AR 086252A1 AR P120101554 A ARP120101554 A AR P120101554A AR P120101554 A ARP120101554 A AR P120101554A AR 086252 A1 AR086252 A1 AR 086252A1
- Authority
- AR
- Argentina
- Prior art keywords
- active ingredient
- amount
- topical formulation
- beclometasone dipropionate
- aqueous phase
- Prior art date
Links
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 title abstract 3
- 229950000210 beclometasone dipropionate Drugs 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 239000012049 topical pharmaceutical composition Substances 0.000 title 1
- 239000008346 aqueous phase Substances 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229950008882 polysorbate Drugs 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 239000003380 propellant Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract 1
- 150000005846 sugar alcohols Chemical class 0.000 abstract 1
- 239000002562 thickening agent Substances 0.000 abstract 1
- 239000012929 tonicity agent Substances 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una formulación farmacéutica sin propelente destinada a una administración tópica, caracterizada porque comprende partículas micronizadas de dipropionato de beclometasona (BDP) como ingrediente activo suspendidas en una fase acuosa para su uso en la profilaxis y/o el tratamiento de una enfermedad dermatológica, donde dicha fase acuosa consiste de un agente emulsionante seleccionado de la clase de los polisorbatos en una cantidad que comprende entre 0,1 y 0,3% p/v, un azúcar o un alcohol de azúcar como agente de tonicidad en una cantidad que comprende entre 5,0 y 5,2% p/v, una mezcla de celulosa microcristalina y carboximetilcelulosa sódica como agente espesante en una cantidad que comprende entre 0,5 y 1,0% p/v, uno o más conservantes, y agua hasta completar el 100%.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11164815 | 2011-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086252A1 true AR086252A1 (es) | 2013-11-27 |
Family
ID=44645358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101554A AR086252A1 (es) | 2011-05-04 | 2012-05-03 | Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8679512B2 (es) |
| EP (1) | EP2704687B1 (es) |
| CN (1) | CN103501765B (es) |
| AR (1) | AR086252A1 (es) |
| BR (1) | BR112013027390A2 (es) |
| CY (1) | CY1116609T1 (es) |
| DK (1) | DK2704687T3 (es) |
| ES (1) | ES2545854T3 (es) |
| RU (1) | RU2600796C2 (es) |
| WO (1) | WO2012150130A1 (es) |
| ZA (1) | ZA201308192B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5833007B2 (ja) | 2009-08-31 | 2015-12-16 | ドクター・レディーズ・ラボラトリーズ・リミテッド | ステロイドを含む局所製剤 |
| US20160184431A1 (en) | 2014-03-11 | 2016-06-30 | Promius Pharma Llc | Topical compositions comprising a corticosteroid |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT73772B (en) * | 1980-10-06 | 1983-10-14 | Glaxo Group Ltd | Topically administrable pharmaceutical compositions containing anti-inflammatory steroids |
| US5158761A (en) | 1989-04-05 | 1992-10-27 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
| DE4316727A1 (de) * | 1993-05-19 | 1994-11-24 | Linden Apotheke Apothekerin Ev | Mittel zur Behandlung von entzündlichen Erkrankungen des unteren Dickdarmbereiches und der Haut mit Beclomethason als Wirkstoff |
| IT1303692B1 (it) | 1998-11-03 | 2001-02-23 | Chiesi Farma Spa | Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione. |
| GB9918559D0 (en) * | 1999-08-07 | 1999-10-06 | Glaxo Wellcome Kk | Novel pharmaceutical formulation |
| AU2003223477A1 (en) | 2002-04-05 | 2003-10-27 | University Of Utah Research Foundation | Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2 |
| US7811606B2 (en) * | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
| JP5833007B2 (ja) * | 2009-08-31 | 2015-12-16 | ドクター・レディーズ・ラボラトリーズ・リミテッド | ステロイドを含む局所製剤 |
-
2012
- 2012-04-18 WO PCT/EP2012/057065 patent/WO2012150130A1/en not_active Ceased
- 2012-04-18 CN CN201280021630.6A patent/CN103501765B/zh not_active Expired - Fee Related
- 2012-04-18 RU RU2013148949/15A patent/RU2600796C2/ru not_active IP Right Cessation
- 2012-04-18 ES ES12720127.5T patent/ES2545854T3/es active Active
- 2012-04-18 EP EP12720127.5A patent/EP2704687B1/en active Active
- 2012-04-18 DK DK12720127.5T patent/DK2704687T3/en active
- 2012-04-18 BR BR112013027390A patent/BR112013027390A2/pt not_active IP Right Cessation
- 2012-05-02 US US13/462,245 patent/US8679512B2/en not_active Expired - Fee Related
- 2012-05-03 AR ARP120101554A patent/AR086252A1/es unknown
-
2013
- 2013-11-01 ZA ZA2013/08192A patent/ZA201308192B/en unknown
-
2015
- 2015-08-13 CY CY20151100715T patent/CY1116609T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2704687T3 (en) | 2015-10-05 |
| WO2012150130A1 (en) | 2012-11-08 |
| HK1187821A1 (en) | 2014-04-17 |
| EP2704687A1 (en) | 2014-03-12 |
| RU2600796C2 (ru) | 2016-10-27 |
| CN103501765B (zh) | 2015-06-17 |
| CY1116609T1 (el) | 2017-03-15 |
| US8679512B2 (en) | 2014-03-25 |
| RU2013148949A (ru) | 2015-05-10 |
| BR112013027390A2 (pt) | 2017-01-17 |
| ZA201308192B (en) | 2015-01-28 |
| ES2545854T3 (es) | 2015-09-16 |
| CN103501765A (zh) | 2014-01-08 |
| EP2704687B1 (en) | 2015-07-08 |
| US20120301511A1 (en) | 2012-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
| CL2017000829A1 (es) | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. | |
| AR059350A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
| CL2016001411A1 (es) | Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina. | |
| MX2016007067A (es) | Microcapsulas lipidicas que comprenden de preferencia un retinoide y composicion que las contiene, su procedimiento de preparacion y su uso en dermatologia. | |
| AR088381A1 (es) | Formulaciones de etanercept estabilizadas con meglumina | |
| MX2014008283A (es) | Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta. | |
| MX2014008284A (es) | Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta. | |
| CO6210803A2 (es) | Formulaciones liquidas formadoras de pelicula dermica para la liberacion de farmaco a la piel | |
| MX382986B (es) | El uso de una cápsula mucoadherente que comprende pululano y cdb-2914 para el tratamiento de un trastorno dependiente de la progesterona | |
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| CL2019002172A1 (es) | Agente terapéutico para enfermedades del hígado. | |
| BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
| AR087488A1 (es) | Uso de composiciones para retrasar el inicio de la fase catagena del cabello | |
| MX2020005921A (es) | Formulaciones y metodos para el suministro vaginal de antiprogestinas. | |
| MX2015011624A (es) | Composiciones farmaceuticas secas que comprenden nanoparticulas de agente activo ligadas a particulas portadoras. | |
| AR086252A1 (es) | Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo | |
| JP2015511618A5 (es) | ||
| AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina | |
| MX2021000769A (es) | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. | |
| CL2015000053A1 (es) | Composicion líquida oral pediátrica que comprende nepadutant y tpgs; proceso para prepararla; util en el tratamiento de enfermedades intestinales. | |
| AR108793A1 (es) | Composiciones que comprenden timolol y un agente antiinflamatorio | |
| CO2020002287A2 (es) | Composiciones farmacéuticas | |
| AR067465A1 (es) | Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente benzodiazepinico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |